20-F: Nymox Pharmaceutical Faces Significant Going Concern Doubts Amidst Continued Losses and Regulatory Setbacks for Key Drug Candidate

Nymox Pharmaceutical Corporation reported a net loss of $4.5 million for 2024, accumulating a deficit of $212.5 million, and disclosed substantial doubt about its ability to continue as a going concern due to insufficient cash and lack of product sales.

Summary

• Nymox Pharmaceutical Corporation reported a net loss of $4,491,797 for the year ended December 31, 2024, an improvement from the $8,844,758 net loss in 2023.
• The company's accumulated deficit reached approximately $212.5 million as of December 31, 2024.
• Total assets stood at $653,752, while total equity was a negative $(6,775,144) as of December 31, 2024.
• Nymox had negative working capital of $6,776,056 and cash flows used in operations of $2,601,188 for the year ended December 31, 2024.
• The company has generated no revenues from product sales for the years ended December 31, 2024, 2023, and 2022.
• Research and development expenditures decreased to $3,280,532 in 2024 from $3,994,809 in 2023, primarily due to reduced U.S. BPH trial activity.
• The Marketing Authorization Application (MAA) for NX-1207 in Denmark ran out of time in July 2024 and requires re-submission with a new fee.
• The MAA for NX-1207 in the U.K. is still under review after being filed in September 2023 and accepted in October 2023.
• The company received a Refusal to File Letter from the FDA in May 2022 for its New Drug Application for NX-1207 and is still formulating a response strategy.
• Management believes current cash balances are insufficient to fund planned business operations and R&D programs over the next 12 months, indicating a material uncertainty about its ability to continue as a going concern.
• The company relies heavily on financing through common stock private purchase agreements and intends to seek additional equity or financing.
• As of April 30, 2025, there were 94,540,140 common shares outstanding, with 6,350,000 share options outstanding as of December 31, 2024.
• Paul Averback, President and CEO, holds 37.0% of beneficially owned and controlled shares, and James G. Robinson, Co-Chairman, holds 8.3% as of April 19, 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial instability, including a going concern warning, negative working capital, and no revenue. Regulatory progress for its lead candidate is stalled or requires re-submission, and there are significant internal control weaknesses. While net loss decreased, the underlying issues remain critical, indicating a highly precarious position.

Positives

• Net loss decreased significantly to $4.5 million in 2024 from $8.8 million in 2023, and loss per share improved from $0.10 to $0.05.
• Cash flows used in operating activities decreased to $2.6 million in 2024 from $4.1 million in 2023, indicating a reduction in cash burn.
• Long-term extension Phase 3 studies (NX02-0017 and NX02-0018) for NX-1207 for BPH successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo, with an excellent safety profile.
• The company has an extensive patent portfolio covering its investigational drug NX-1207 and other therapeutic/diagnostic indications, including U.S. and global patent rights for statin drugs for Alzheimer's disease.
• Preclinical studies of NX-1207 showed positive results for hepatocellular carcinoma (HCC), with the company intending to advance to human clinical trials for this indication.
• The company has settled several legal proceedings, including the Bahamas Derivative Action and the Texas/California actions against Mr. Cutler, and dismissed the Delaware action against Ascella Health LLC.

Negatives

• The company has never made a profit and has incurred substantial operating losses since its inception, with an accumulated deficit of approximately $212.5 million as of December 31, 2024.
• Nymox has negative working capital of $6,776,056 as of December 31, 2024, and very low cash balances of $74,000.
• Management explicitly states that current cash balances and anticipated funds from product sales are not sufficient to fund planned business operations over the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• The Marketing Authorization Application (MAA) for NX-1207 with the Danish Medicines Agency (DKMA) ran out of time and requires re-submission with a new fee.
• The FDA issued a Refusal to File Letter for the New Drug Application (NDA) for NX-1207, and the company is still formulating a response strategy.
• The company has no revenues from product sales for the past three fiscal years (2022-2024).
• The company relies heavily on financing through the issuance of common stock, which has led to significant shareholder dilution, with common shares outstanding increasing to 94,540,140 as of April 30, 2025.
• Material weaknesses in internal control over financial reporting were identified, including a lack of documented policies and procedures, risk of management override, and insufficient separation of duties.
• The earliest expiry date for U.S. patents covering NX-1207 is 2022, raising concerns about long-term intellectual property protection without extensions.

Risks

• The company may not receive the required regulatory approvals necessary to commercialize its therapeutic products in development, such as Fexapotide Triflutate (NX-1207), as clinical trials are lengthy, complex, expensive, and uncertain.
• Clinical trials for therapeutic products may be delayed, making it difficult to achieve anticipated development or commercialization timelines, as evidenced by past delays and the FDA's Refusal to File letter for NX-1207.
• A setback in efforts to obtain regulatory clearance for products would likely cause a significant drop in the price of the company's shares, as seen historically (e.g., 82% drop in November 2014).
• The company may not be able to make adequate arrangements with third parties for the commercialization of its product candidates, such as NX-1207, on favorable terms, impacting revenue generation.
• The company may not achieve its projected development goals in the time frames announced and expected, due to factors like clinical trial delays, regulatory uncertainties, and manufacturing/marketing arrangement delays.
• Even if regulatory approvals are obtained, the company will be subject to stringent ongoing government regulation, which is expensive and consumes substantial resources, potentially requiring costly post-marketing studies or leading to product limitations/revocations.
• The company faces significant and growing competition in the pharmaceutical and biotechnology industries, particularly for BPH treatments, from numerous existing drugs and surgical/thermal procedures.
• Protecting patents and proprietary information is costly and difficult, and there is no assurance that additional patents will be issued, existing patents will be commercially beneficial, or that the company can operate without infringing on others' rights.
• Changing market conditions in the healthcare industry, including potential drug price limits and changes in reimbursement policies by health care plans (e.g., Medicare/Medicaid), could adversely affect product pricing and market growth.
• The company is subject to continuing potential product liability risks, which could lead to costly claims, product recalls, and financial harm, and its insurance coverage may not be sufficient.
• The issuance of new shares to fund operations may dilute Nymox's stock and lower its share price.
• The company faces potential losses due to foreign currency exchange risks, primarily between the U.S. dollar and the Canadian dollar, although recent impact has been minimal.
• Cybersecurity breaches and other disruptions could compromise information, result in unauthorized disclosure of confidential data, damage reputation, and expose the company to liability.
• The company's ability to raise capital through equity financing and other sources will be impacted by the market price and trading volumes of its common shares, and favorable terms for additional funding are not assured.

Future Outlook

Nymox Pharmaceutical Corporation anticipates continued operating losses for at least the next few years due to ongoing research and development expenditures. The company expects revenues to significantly increase only if and when product candidates pass clinical trials and are successfully launched on the market. Management believes current cash balances are insufficient to fund planned operations for the next 12 months and intends to seek additional equity or other financing, primarily through existing private placements and/or other sources of capital. The company also plans to advance NX-1207 into human clinical trials for hepatocellular carcinoma (HCC) and continues to formulate a strategy to respond to the FDA's Refusal to File Letter for NX-1207 for BPH.

Management Comments

• "Management believes that current cash balances as at December 31, 2024 and anticipated funds from product sales will not be sufficient to fund its planned business operations and research and development programs over the next 12 months."
• "The Corporations primary sources of financing since 2003 has been the Common Stock Private Purchase Agreement. If necessary, the Corporation intends to seek additional equity or finance through the existing private placements and/or other sources of capital in order to fund these operations and activities over the next year."
• "Considering recent developments and the need for additional financing, there exists a material uncertainty that casts substantial doubt about the Corporations ability to continue as a going concern."
• "The development of therapeutic candidates and of moving therapeutic product candidates through clinical trials and regulatory review and approval is a priority for the Corporation currently. The growth of sales will become more of a priority once these candidates have reached the marketing stage."
• "The Corporation expects that revenues will significantly increase if and when product candidates pass clinical trials and are launched on the market."
• "The Corporation expects that research and development expenditures will decrease more as a result of the Corporations U.S. BPH trial activity reduction, pending the evaluation of the data."
• "Because of the early stage of development and the uncertainty related to the Corporations R&D projects, it is impossible to outline the nature, timing or estimated costs of the efforts necessary to complete these projects, nor the anticipated completion dates for these projects."
• "The Corporation expects that general and administrative expenditures will increase if and when product development leads to expanded operations."

Industry Context

Nymox operates in the highly competitive biopharmaceutical industry, particularly in the therapeutic areas of enlarged prostate (BPH) and prostate cancer. The BPH market is saturated with numerous approved proprietary and generic drugs (e.g., Avodart, Flomax, Cialis, finasteride) and various surgical/thermal treatments (e.g., TURP, Urolift system). This intense competition poses a significant challenge for Nymox's lead candidate, NX-1207, which has faced substantial regulatory hurdles and delays. The broader healthcare industry is also undergoing transitions, with potential for drug price limitations and changes in reimbursement policies (e.g., Patient Protection and Affordable Care Act), which could further impact the commercial viability of Nymox's products if they ever reach the market. The long development timelines and high costs associated with bringing new drugs to market, especially cancer therapeutics, are typical industry challenges that Nymox is experiencing.

Comparison to Industry Standards

• Nymox's lack of revenue from product sales for multiple years is significantly below industry standards for companies seeking to commercialize drug candidates, as successful biopharmaceutical companies typically generate revenue from existing products or licensing agreements to offset R&D costs.
• The company's accumulated deficit of over $212 million and persistent negative working capital are indicative of a prolonged development phase without commercial success, a common but severe challenge for small-cap biotech firms, contrasting sharply with profitable, established pharmaceutical companies like Pfizer or Johnson & Johnson.
• The regulatory setbacks for NX-1207, including the FDA's Refusal to File letter and the Danish MAA running out of time, highlight a struggle to meet stringent regulatory requirements, which is a critical hurdle that many drug candidates fail to overcome, unlike successful approvals seen by competitors with BPH drugs such as Eli Lilly's Cialis or GlaxoSmithKline's Avodart.
• Nymox's reliance on private placements and related-party loans for financing, coupled with significant share dilution, is a common characteristic of early-stage or struggling biotech companies that lack access to broader capital markets or significant partnership deals, unlike larger firms that can fund R&D through robust cash flows or less dilutive debt financing.
• The company's identified material weaknesses in internal control over financial reporting (lack of documented policies, management override risk, insufficient segregation of duties) fall below best practices for corporate governance and financial integrity, which are typically robust in mature, publicly traded companies to ensure reliable financial reporting.

Management Changes

Corporate Governance

Legal Proceedings

• The Canadian Revenue Authorities (CRA) is asserting that the company owes additional taxes for the domicile move from Canada to the Bahamas, which the company disputes and is contesting.
• An application for Injunctive Relief and a Derivative Action filed against the company in the Supreme Court of The Bahamas (Claim No. 2023/COM/com/0057) was terminated on March 21, 2024, with the court ordering the claimants to pay the company costs and damages (determination pending).
• Nymox filed an action in the Superior Court of California, County of Orange (Case No. 30-2023-01358191-CU-BC-WJC) against Randall Lanham, M. Richard Cutler, Chris Riley, and Committee to Restore Nymox Share Value for breaches of fiduciary duties, trade secret misappropriation, etc. A temporary restraining order and preliminary injunction were granted. The matter against Mr. Cutler has been settled, and the trial for other defendants is set for October 2025.
• A lawsuit filed by Mr. Cutler in Harris County, Texas, against Nymox Pharmaceutical Corporation seeking payment for past legal invoices was settled on August 19, 2024, resolving all related actions against Mr. Cutler in Texas, California, and the Bahamas.
• An action filed by Nymox against Ascella Health LLC in the United States District Court for the District of Delaware (Case 1:24-cv-00189-UNA) alleging misappropriation of trade secrets, breach of contract, etc., was dismissed by Nymox on March 7, 2025.

Related Party Transactions

• The company received multiple short-term advances from Paul Averback, the President and CEO, primarily for payroll and working capital, with an outstanding balance of $15,000 as of December 31, 2024.
• The company has engaged in multiple funding arrangements with James G. Robinson, a director and Co-Chairman, involving loans and equity issuances. As of December 31, 2024, the total loan amount from Mr. Robinson was $3,340,752, with accrued interest of $218,774.93.
• An Addendum to the loan agreement with James G. Robinson, dated November 14, 2024, extends the total loan amount to at least $3,000,000 and provides Mr. Robinson with an option to convert the amount due plus interest into common shares at $0.30 per share until December 31, 2026.
• Patrick Doody, Vice President and General Counsel, received 1,000,000 restricted shares in 2024 as compensation.
• 7.5 million restricted shares, valued at $3,811,388, are owed to Dr. Averback in compensation back pay pursuant to an implied contract, with $2,354,807 attributable to G&A and $1,456,581 to R&D.
• Stock and stock option-based compensation expense to directors and employees totaled $671,151 in 2024, with $300,938 for G&A and $370,214 for R&D.
• Key management personnel compensation, including salary, short-term benefits, and stock-based compensation, totaled $673,000 in 2024.
• Payments were made to corporations controlled by former officers for services rendered, including $46,066 to the former CFO's controlled corporation in 2023 and $141,717 to the former Corporate Legal Counsel's controlled corporation in 2023.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk due to the company's reliance on issuing common shares for financing. Existing shareholders have experienced substantial value erosion, with the stock price falling significantly after past clinical trial failures. The ongoing going concern uncertainty poses a high risk of further loss of investment.
• **Employees**: The company's precarious financial position and reliance on continued financing create job insecurity. Compensation for key executives includes substantial stock-based awards, aligning their interests with share value, but also reflecting the company's cash constraints.
• **Customers**: Currently, there are no product sales, so there is no direct impact on customers. Future customers for NX-1207, if approved, would benefit from a new treatment option for BPH or prostate cancer, but the delays and regulatory hurdles mean this benefit is uncertain and distant.
• **Suppliers**: The company's negative working capital and reliance on external financing could pose payment risks for suppliers, although the document does not explicitly detail supplier relationships.
• **Creditors**: James G. Robinson, a director, is a significant creditor through loans, some of which are convertible to equity, indicating a close financial relationship and potential for debt-to-equity conversion rather than cash repayment.

Next Steps

• Formulate a strategy to respond to the FDA's Refusal to File Letter for the NX-1207 New Drug Application.
• Re-submit the Marketing Authorization Application (MAA) for NX-1207 to the Danish Medicines Agency (DKMA) with a new fee.
• Continue working towards definitive studies and data review for NX-1207 for prostate cancer, and potential regulatory review filings in other jurisdictions.
• Advance NX-1207 into human clinical trials for the treatment of hepatocellular carcinoma (HCC).
• Seek additional equity or other financing through existing private placements and/or other sources of capital to fund operations over the next year.
• Implement procedures to address material weaknesses in internal control over financial reporting, including improving documented policies, mitigating management override risk, and enhancing segregation of duties.
• Determine costs and damages to be paid by claimants in the terminated Bahamas Derivative Action.

Key Dates

Recommendation

Keywords

Biopharmaceutical, NX-1207, BPH, Prostate Cancer, Drug Development, Clinical Trials, Regulatory Approval, SEC Filing, Going Concern, Pharmaceutical, Biotechnology, Fexapotide Triflutate, Alzheimer's Disease, Hepatocellular Carcinoma, Patent Portfolio, Share Dilution, OTC Markets